In its 2024 opinion in Vanegas v. Signet Builders, Inc., the U.S. Court of Appeals for the Seventh Circuit joined a growing number of federal ...
The Board also approved a Miss. State career center funded through the U.S. Department of Education Rehabilitation Services ...
Ozanimodâ–¼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...
Results of 3 trials revealed that omitting transplant did not impact progression or survival outcomes for pediatric, ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...
Clinicians may one day be able to treat immune checkpoint inhibitor-related myocarditis without disrupting cancer therapy, findings from a cellular investigation showed.Individuals who die of immune ...
(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...
This was the stock's third consecutive day of gains.
For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...
The two biggest questions for SCHD right now are 1) what’s caused it to underperform so badly, even within its category and 2) will those trends continue into 2025.
Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive ...